NRD
TSHA icon

Nebula Research & Development’s Taysha Gene Therapies TSHA Stock Holding History

Nebula Research & Development’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-21,737
Closed -$43.7K – 1121
2024
Q3 		$43.7K Buy
+21,737
New +$47.7K 0.01% 899

Other funds holding TSHA

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nebula Research & Development's TSHA Position: Q4 2024 in Review

Nebula Research & Development sold out of Taysha Gene Therapies (TSHA) in Q4 2024, closing a stake of 21,737 shares — an estimated $43.7K sold.

Nebula Research & Development first reported a position in TSHA in Q3 2024 and held it in 1 quarter. The position peaked at $43.7K in Q3 2024. 131 funds tracked by Wall St. Rank hold TSHA as of Q4 2024.

  • Nebula Research & Development reported no remaining Taysha Gene Therapies position as of Q4 2024 after selling out during the quarter.
  • Nebula Research & Development sold 21,737 Taysha Gene Therapies shares in Q4 2024, an estimated $43.7K.
  • Nebula Research & Development first reported a position in Taysha Gene Therapies in Q3 2024 and held it in 1 quarter.
  • Nebula Research & Development's Taysha Gene Therapies position peaked at $43.7K in Q3 2024.
  • 131 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q4 2024.

Based on Nebula Research & Development's 13F filing for Q4 2024, filed 14 Feb 2025.